Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients

Baqer et al., Medical Forum Monthly, doi:10.60110/medforum.360407, Apr 2025
https://c19early.org/baqer.html
Curcumin for COVID-19
16th treatment shown to reduce risk in February 2021, now with p = 0.0000000061 from 28 studies.
No treatment is 100% effective. Protocols combine treatments.
5,900+ studies for 172 treatments. c19early.org
Open-label RCT 58 COVID-19 patients in Iraq reporting lower D-dimer with curcumin. No clinical endpoints (mortality, ICU admission, mechanical ventilation, length of stay) were reported, despite the abstract’s claim of mortality reduction. No baseline group details are reported other than gender, and the study was not registered.
Baqer et al., 30 Apr 2025, Iraq, peer-reviewed, 6 authors, study period 1 February, 2020 - 31 July, 2020. Contact: maiss@esraa.edu.iq.
Abstract: Med. Forum, Vol. 36, No. 4 31 April, 2025 Original Article Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients Anticoagulant Effect of Curcumin in Covid-19 Maiss S. Baqer1, Saifan A Dushan1, Rafif Raad1, Rabab Mohammed Noori Hameed1, Ayaashraf Ahmed1 and Basim Dhawi Dakhil2 ABSTRACT Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19 patients. Study Design: Randomized open-labelled controlled trial study. Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University, Baghdad, Iraq from 1st February 2020 to 31st July 2020. Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily. Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P<0.05). Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when used as an adjunct to enoxaparin. Key Words: Curcumin, D-dimer, Enoxaparin, COVID-19, Anticoagulant effect Citation of article: Baqer MS, Dushan SA, Raad R, Hameed RMN, Ahmed A, Dakhil BD. Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients. Med Forum 2025;36(4):31-34. doi:10.60110/medforum.360407.
DOI record: { "DOI": "10.60110/medforum.360407", "ISSN": [ "2519-7134", "1029-385X" ], "URL": "http://dx.doi.org/10.60110/medforum.360407", "abstract": "<jats:p>Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19 patients. Study Design: Randomized open-labelled controlled trial study. Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University, Baghdad, Iraq from 1st February 2020 to 31st July 2020. Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily. Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated  with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P&lt;0.05). Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when used as an adjunct to enoxaparin. </jats:p>", "author": [ { "affiliation": [], "family": "Baqer", "given": "Maiss S.", "sequence": "first" }, { "affiliation": [], "family": "Dushan", "given": "Saifan A", "sequence": "additional" }, { "affiliation": [], "family": "Raad", "given": "Rafif", "sequence": "additional" }, { "affiliation": [], "family": "Noori Hameed", "given": "Rabab Mohammed", "sequence": "additional" }, { "affiliation": [], "family": "Ahmed", "given": "Ayaashraf", "sequence": "additional" }, { "affiliation": [], "family": "Dakhil", "given": "Basim Dhawi", "sequence": "additional" } ], "container-title": "Medical Forum Monthly", "container-title-short": "mfm", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 5, 26 ] ], "date-time": "2025-05-26T19:26:24Z", "timestamp": 1748287584000 }, "deposited": { "date-parts": [ [ 2025, 5, 26 ] ], "date-time": "2025-05-26T19:29:56Z", "timestamp": 1748287796000 }, "indexed": { "date-parts": [ [ 2025, 5, 26 ] ], "date-time": "2025-05-26T20:10:09Z", "timestamp": 1748290209227, "version": "3.41.0" }, "is-referenced-by-count": 0, "issue": "4", "issued": { "date-parts": [ [ 2025, 4, 30 ] ] }, "journal-issue": { "issue": "4", "published-online": { "date-parts": [ [ 2025, 5, 26 ] ] } }, "link": [ { "URL": "http://medicalforummonthly.com/index.php/mfm/article/download/5253/4728", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://medicalforummonthly.com/index.php/mfm/article/download/5253/4728", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "39730", "original-title": [], "prefix": "10.60110", "published": { "date-parts": [ [ 2025, 4, 30 ] ] }, "published-online": { "date-parts": [ [ 2025, 4, 30 ] ] }, "publisher": "Medical Academic Foundation", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://medicalforummonthly.com/index.php/mfm/article/view/5253" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients", "type": "journal-article", "volume": "36" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit